keyword
MENU ▼
Read by QxMD icon Read
search

renal dose adjustment

keyword
https://www.readbyqxmd.com/read/28528130/increased-body-mass-index-is-a-risk-factor-for-end-stage-renal-disease-in-the-chinese-singapore-population
#1
Quan-Lan Jasmine Lew, Tazeen Hasan Jafar, Mohammad Talaei, Aizhen Jin, Khuan Yew Chow, Jian-Min Yuan, Woon-Puay Koh
The relationship between body mass index (BMI) and end-stage renal disease (ESRD) is confounded by co-morbidities associated with both conditions. Furthermore, the association at low range BMI is controversial. We studied this association in the Singapore Chinese Health Study, a population-based prospective cohort that recruited Singaporean Chinese men and women 45-74 years of age from 1993 to 1998. Self-reported weight, height, lifestyle factors, usual diet, and medical history were collected via an interviewer-administered questionnaire...
May 18, 2017: Kidney International
https://www.readbyqxmd.com/read/28524005/rivaroxaban-metabolism-pharmacologic-properties-and-drug-interactions
#2
Tomas Kvasnicka, Ivana Malikova, Zuzana Zenahlikova, Karolína Kettnerova, Radka Brzezkova, Tomas Zima, Jan Ulrych, Jan Briza, Ivan Netuka, Jan Kvasnicka
BACKGROUND: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action. OBJECTIVE: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban...
May 18, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28515811/first-line-sunitinib-or-pazopanib-in-metastatic-renal-cell-carcinoma-the-canadian-experience
#3
Aly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, Lori Wood, Austin Kalirai, Georg A Bjarnason, Hao-Wen Sim, Christian K Kollmannsberger, Anil Kapoor, Sebastien J Hotte, Marie Vanhuyse, Piotr Czaykowski, M Neil Reaume, Denis Soulieres, Peter Venner, Scott North, Naveen S Basappa
INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting. METHODS: Data were collected on mRCC patients using the prospective Canadian Kidney Cancer Information System (CKCis) database from January 2011 to November 2015...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28511545/fosfomycin-tromethamine-for-the-treatment-of-cystitis-in-abdominal-solid-organ-transplant-recipients-with-renal-dysfunction
#4
Luiza Kerstenetzky, Margaret R Jorgenson, Jillian L Descourouez, Glen Leverson, Warren E Rose, Robert R Redfield, Jeannina A Smith
BACKGROUND: Urinary tract infection (UTI) after abdominal solid organ transplantation (SOT) is associated with significant morbidity and mortality. Fosfomycin tromethamine (FOS), a uroselective antibiotic, is FDA approved for uncomplicated UTIs in women and is used off-label for complicated UTIs and prostatitis in men. Literature supporting the use of FOS in the SOT population is limited, and efficacy is questioned in the setting of renal dysfunction. OBJECTIVE: To evaluate the success of FOS for the treatment of cystitis in SOT patients with renal dysfunction...
May 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28508324/impact-of-clinical-pharmacist-intervention-in-anticoagulation-clinic-in-sudan
#5
Nahid Osman Ahmed, Bashier Osman, Yassein Mohamed Abdelhai, Tariq Muhammed Hashim El-Hadiyah
Background Many trials have compared anticoagulation management provided by a pharmacist led anticoagulation clinic versus usual physician care showing the role for clinical pharmacist in the management of anticoagulant therapy, and demonstrating excellent outcomes. In Sudan, there is no published research evaluating the role of pharmacist in providing pharmaceutical care for patients taking warfarin. Objective The objective of the study is to assess the role of clinical pharmacist intervention in warfarin patients compared to usual medical care...
May 15, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28493506/alemtuzumab-dose-adjusted-for-body-weight-is-associated-with-earlier-lymphocyte-repletion-and-less-infective-episodes-in-the-first-year-post-renal-transplantation
#6
Michelle Willicombe, Dawn Goodall, Adam G McLean, David Taube
The optimal dose of alemtuzumab for renal transplant induction is not known and the doses reported in the literature vary. This study compares 2 separate dosing regimens of alemtuzumab in renal transplantation. The first is a standard fixed dose of 30mg (SD) and the second is a dose adjusted for body weight at 0.04mg/kg (AD). In this first-year post transplant, there was no difference in patient [HR 0.64 (0.22-1.86), p=0.39] or allograft survival [HR 1.18 (0.48-2.90), p=0.72] between the two groups. There was also no difference in overall rejection free survival [HR 1...
May 11, 2017: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/28487576/risk-factors-for-nephrotoxicity-associated-with-cisplatin
#7
Karine Almanric, Nathalie Marceau, Ariane Cantin, Émilie Bertin
BACKGROUND: Cisplatin-induced nephrotoxicity occurs in about one-third of patients who receive this chemotherapy drug. In late 2012, the study institution began measuring serum creatinine on day 7 after administration of cisplatin to identify patients with acute renal failure. OBJECTIVE: To evaluate the extent of nephrotoxicity associated with cisplatin and the influence of risk factors for nephrotoxicity. METHODS: This retrospective study involved patients who received a first cycle of cisplatin-based chemotherapy between November 1, 2012, and November 1, 2013...
March 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28485363/study-of-efficacy-and-safety-of-modified-adjuvant-intraperitoneal-chemotherapy-regimen-in-carcinoma-ovary
#8
P Dash, V Goel, V Talwar, D C Doval, S Raina, P Goyal, A Upadhyay, N Patnaik
OBJECTIVE: It has been demonstrated in few trials that intraperitoneal and intravenous (IP/IV) chemotherapy improves survival in advanced stage ovarian cancer (OC). However, in view of high treatment-related toxicities, various modifications in treatment schedules have been tried. In this study, response and tolerability of IP paclitaxel on day 8 with IV paclitaxel on day 1 and IV cisplatin day 2 in carcinoma ovary were evaluated. PATIENTS AND METHODS: In this prospective observational study, from March 2013 to December 2015, the efficacy and tolerability of adjuvant IP/IV chemotherapy in optimally cytoreduced Stage III epithelial OC (EOC) patients were assessed...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28484587/reducing-error-in-anticoagulant-dosing-via-multidisciplinary-team-rounding-at-point-of-care
#9
Munish Sharma, Mahesh Krishnamurthy, Richard Snyder, James Mauro
The incorporation of a clinical pharmacist in daily rounding can help identify and correct errors related to anticoagulation dosing. Inappropriate anticoagulant dosing increases the risk of developing significant bleeding diathesis. Conversely, inappropriate dosing may also fail to produce a therapeutic response. We retrospectively reviewed electronic medical records of 41 patients to confirm and analyze the errors related to various anticoagulants. A clinical pharmacist in an integrated rounding between the period of February 2016 and April 2016 collected this data...
April 6, 2017: Clinics and Practice
https://www.readbyqxmd.com/read/28484294/interobserver-variability-in-interpretation-of-planar-and-spect-tc-99m-dmsa-renal-scintigraphy-in-children
#10
Nermina Beslic, Renata Milardovic, Amera Sadija, Lejla Dzananovic, Semra Cavaljuga
OBJECTIVE: This study objective was to evaluate interobserver agreement between individual pairs of three nuclear medicine physicians in interpretation of renal cortical scintigraphy in children with respect to the mode of acquisition (planar vs. SPECT), diagnoses and kidney site (left vs. right). MATERIALS AND METHODS: Thirty children were imaged in planar and SPECT mode per protocol upon the injection of Tc-99m DMSA dose adjusted to their body weight. Patients were classified according to diagnoses into four groups...
March 2017: Acta Informatica Medica: AIM
https://www.readbyqxmd.com/read/28479233/addition-of-gemcitabine-to-paclitaxel-epirubicin-and-cyclophosphamide-adjuvant-chemotherapy-for-women-with-early-stage-breast-cancer-tango-final-10-year-follow-up-of-an-open-label-randomised-phase-3-trial
#11
Helena M Earl, Louise Hiller, Helen C Howard, Janet A Dunn, Jennie Young, Sarah J Bowden, Michelle McDermaid, Anna K Waterhouse, Gregory Wilson, Rajiv Agrawal, Susan O'Reilly, Angela Bowman, Diana M Ritchie, Andrew Goodman, Tamas Hickish, Karen McAdam, David Cameron, David Dodwell, Daniel W Rea, Carlos Caldas, Elena Provenzano, Jean E Abraham, Peter Canney, John P Crown, M John Kennedy, Robert Coleman, Robert C Leonard, James A Carmichael, Andrew M Wardley, Christopher J Poole
BACKGROUND: The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel. METHODS: tAnGo was an international, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication for chemotherapy, any nodal status, any hormone receptor status, Eastern Cooperative Oncology Group performance status of 0-1, and adequate bone marrow, hepatic, and renal function...
May 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28473361/seizure-induced-by-sudden-cessation-of-pregabalin-in-a-patient-with-chronic-kidney-disease
#12
Yang Timothy Du, Anthony P Roberts, David J Torpy
A middle-aged woman with diabetic nephropathy on pregabalin for neuropathic pain presented with a diarrhoeal illness. She was found to have acute on chronic renal impairment with an estimated glomerular filtration rate (eGFR) of 10 mL/min, and her usual 150 mg/day of pregabalin was abruptly ceased. Although renal recovery to her baseline of eGFR 15 mL/min was achieved within 3 days, her pregabalin was not restarted. She suffered a tonic-clonic seizure 4 days later, thought to be due to pregabalin withdrawal as there were no other likely causes identified...
May 3, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28465376/therapeutic-considerations-for-antihyperglycemic-agents-in-diabetic-kidney-disease
#13
Joshua J Neumiller, Radica Z Alicic, Katherine R Tuttle
Diabetic kidney disease is among the most frequent complications of diabetes, with approximately 50% of patients with ESRD attributed to diabetes in developed countries. Although intensive glycemic management has been shown to delay the onset and progression of increased urinary albumin excretion and reduced GFR in patients with diabetes, conservative dose selection and adjustment of antihyperglycemic medications are necessary to balance glycemic control with safety. A growing body of literature is providing valuable insight into the cardiovascular and renal safety and efficacy of newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glucose cotransporter 2 inhibitor classes of medications...
May 2, 2017: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/28459916/direct-oral-anticoagulants-doacs-current-status-among-distinct-patient-subgroups
#14
Peter Riley, Abhishek Maan, Kenneth S Korr
The landscape of anticoagulant therapy for atrial fibrillation and deep-vein thrombosis has evolved considerably in the last decade with the advent of Novel or Direct-Acting Oral Antiocoagulants (DOACs). The initial phase III randomized controlled trials established the individual DOACs as viable alternatives to warfarin for thromboprophylaxis but generalizations to the larger population were limited by the small number of protocol subjects with renal insufficiency, congestive heart failure, advanced age and other comorbidities...
May 1, 2017: Rhode Island Medical Journal
https://www.readbyqxmd.com/read/28456704/outpatient-treatment-of-osteomyelitis-with-telavancin
#15
Claudia P Schroeder, Lucinda J Van Anglen, Robin H Dretler, John S Adams, Richard C Prokesch, Quyen Luu, Andrew H Krinsky
Telavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens including Staphylococcus aureus, the most frequent cause of osteomyelitis. Treatment is often challenging due to needs for surgical intervention along with prolonged administration of intravenous antimicrobials, frequently in an outpatient setting. This was a retrospective analysis of the efficacy and safety of telavancin for treatment of osteomyelitis provided as outpatient parenteral antimicrobial therapy (OPAT) in physician office infusion centres...
April 26, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28452920/high-tacrolimus-clearance-is-a-risk-factor-for-acute-rejection-in-the-early-phase-after-renal-transplantation
#16
Erlend Johannessen Egeland, Ida Robertsen, Monica Hermann, Karsten Midtvedt, Elisabet Størset, Marte Theie Gustavsen, Anna Varberg Reisæter, Rolf Klaasen, Stein Bergan, Hallvard Holdaas, Anders Hartmann, Anders Åsberg
BACKGROUND: Patients with high tacrolimus clearance eliminate more drug within a dose interval compared to those with low clearance. Delays in dosing time will result in transient periods of lower concentrations in high versus low clearance patients. Transient subtherapeutic tacrolimus concentrations may induce acute rejection episodes. METHODS: A retrospective study in all renal transplant patients treated with tacrolimus at our centre from 2009 to 2013 was conducted...
April 27, 2017: Transplantation
https://www.readbyqxmd.com/read/28451896/prospective-analysis-of-long-term-renal-function-in-survivors-of-childhood-wilms-tumor
#17
Marie A Neu, Alexandra Russo, Arthur Wingerter, Francesca Alt, Johanna Theruvath, Khalifa El Malki, Bettina Kron, Matthias Dittrich, Johannes Lotz, Raimund Stein, Rolf Beetz, Joerg Faber
BACKGROUND: Considering the improved outcome, a better understanding of the late effects in Wilms tumor survivors (WT-S) is needed. This study was aimed at evaluating renal function and determining the prevalence of clinical and subclinical renal dysfunction in a cohort of WT-S using a multimodal diagnostic approach. METHODS: Thirty-seven WT-S were included in this prospective cross-sectional single center study. To evaluate renal function, glomerular filtration rate (GFR) and urinary protein excretion were assessed...
April 28, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28449324/efficacy-and-safety-of-lixisenatide-in-patients-with-type-2-diabetes-and-renal-impairment
#18
M Hanefeld, J M Arteaga, L A Leiter, G Marchesini, E Nikonova, M Shestakova, W Stager, R Gómez-Huelgas
AIMS: This post hoc assessment evaluated the efficacy and safety of once-daily, prandial glucagon-like peptide-1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (eGFR ≥90 mL/min), or mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment. METHODS: Patients from nine lixisenatide trials in the GetGoal clinical trial programme were categorized by baseline creatinine clearance: normal renal function (lixisenatide n = 2094, placebo n = 1150); renal impairment (mild: lixisenatide n = 637, placebo n = 414; moderate: lixisenatide n = 122, placebo n = 68)...
April 27, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28446744/levetiracetam-pharmacokinetics-in-a-patient-with-intracranial-hemorrhage-undergoing-continuous-veno-venous-hemofiltration
#19
Edward T Van Matre, Scott W Mueller, Douglas N Fish, Robert MacLaren, Luis F Cava, Robert T Neumann, Tyree H Kiser
BACKGROUND Levetiracetam is an antiepileptic drug frequently used in critically ill patients. Levetiracetam is primarily eliminated as a parent compound via glomerular filtration and requires dose adjustment in renal insufficiency, but the literature on patients receiving continuous veno-venous hemofiltration (CVVH) is scant. CASE REPORT We report the levetiracetam pharmacokinetic profile of a patient being treated with levetiracetam 1000 mg intravenously every 12 h who required continuous veno-venous hemofiltration (CVVH)...
April 27, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28444760/vancomycin-levels-are-frequently-subtherapeutic-in-critically-ill-patients-a-prospective-observational-study
#20
V Bakke, H Sporsem, E Von der Lippe, I Nordøy, Y Lao, H C Nyrerød, L Sandvik, K R Hårvig, J F Bugge, E Helset
BACKGROUND: Appropriate utilization of vancomycin is important to attain therapeutic targets while avoiding clinical failure and the development of antimicrobial resistance. Our aim was to observe the use of vancomycin in an intensive care population, with the main focus on achievement of therapeutic serum concentrations (15-20 mg/l) and to evaluate how this was influenced by dose regimens, use of guidelines and therapeutic drug monitoring. METHODS: A prospective observational study was carried out in the intensive care units at two tertiary hospitals in Norway...
April 25, 2017: Acta Anaesthesiologica Scandinavica
keyword
keyword
86723
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"